Refractory Hodgkin Lymphoma

Also known as: Refractory Hodgkin lymphoma / Hodgkin's disease refractory / Refractory Hodgkin's lymphoma / Refractory Hodgkin's disease / Hodgkin's disease NOS refractory

DrugDrug NameDrug Description
DB06769BendamustineBendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
DB08870Brentuximab vedotinBrentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post treatment [L1737]. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [L1737]. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens [L1737]. Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [L1737]. The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [L1739].
DB00958CarboplatinAn organoplatinum compound that possesses antineoplastic activity.
DB00262CarmustineA cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
DB00515CisplatinCisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
DB01206LomustineAn alkylating agent of value against both hematologic malignancies and solid tumors.
DB09035NivolumabNivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This molecule was produced entirely on mice and grafted onto human kappa and IgG4 Fc region with the mutation _S228P_ for additional stability and reduced variability.[A35203] It is developed by Bristol Myers Squibb and originally FDA approved on December 22, 2014. Since this approval, nivolumab has been approved for a variety of other uses related to cancer therapy. On 2017, was notably approved for the treatment of hepatocellular carcinoma[L3632] and on July 11, 2018, the FDA approved this agent in combination with low doses of [ipilimumab] for the treatment of MSI-H/dMMR metastatic colorectal cancer.[L3611]
DrugDrug NameTargetType
DB06769BendamustineCytochrome P450 1A2enzyme
DB08870Brentuximab vedotinTumor necrosis factor receptor superfamily member 8target
DB08870Brentuximab vedotinCytochrome P450 3A4enzyme
DB08870Brentuximab vedotinATP-binding cassette sub-family B member 5transporter
DB00958CarboplatinHigh affinity copper uptake protein 1transporter
DB00958CarboplatinProbable low affinity copper uptake protein 2transporter
DB00958CarboplatinXanthine dehydrogenase/oxidaseenzyme
DB00958CarboplatinGlutathione S-transferase theta-1enzyme
DB00958CarboplatinSuperoxide dismutase [Cu-Zn]enzyme
DB00958CarboplatinGlutathione S-transferase Penzyme
DB00958CarboplatinGlutathione S-transferase Mu 1enzyme
DB00958CarboplatinNAD(P)H dehydrogenase [quinone] 1enzyme
DB00958CarboplatinCopper-transporting ATPase 1transporter
DB00958CarboplatinCopper-transporting ATPase 2transporter
DB00958CarboplatinATP-binding cassette sub-family G member 2transporter
DB00958CarboplatinCanalicular multispecific organic anion transporter 1transporter
DB00262CarmustineGlutathione reductase, mitochondrialtarget
DB00262CarmustineCytochrome P450 1A2enzyme
DB00515CisplatinCanalicular multispecific organic anion transporter 2transporter
DB00515CisplatinMultidrug resistance-associated protein 5transporter
DB00515CisplatinCanalicular multispecific organic anion transporter 1transporter
DB00515CisplatinSolute carrier family 22 member 2transporter
DB00515CisplatinHigh affinity copper uptake protein 1transporter
DB00515CisplatinProbable low affinity copper uptake protein 2transporter
DB00515CisplatinMultidrug resistance-associated protein 6transporter
DB00515CisplatinMultidrug resistance protein 1transporter
DB00515CisplatinCopper-transporting ATPase 2transporter
DB00515CisplatinCopper-transporting ATPase 1transporter
DB00515CisplatinProstaglandin G/H synthase 2enzyme
DB00515CisplatinXanthine dehydrogenase/oxidaseenzyme
DB00515CisplatinArylamine N-acetyltransferaseenzyme
DB00515CisplatinCytochrome P450 2C9enzyme
DB00515CisplatinCytochrome P450 2B6enzyme
DB00515CisplatinCytochrome P450 4A11enzyme
DB00515CisplatinATP-binding cassette sub-family G member 2transporter
DB00515CisplatinGlutathione S-transferase theta-1enzyme
DB00515CisplatinSuperoxide dismutase [Cu-Zn]enzyme
DB00515CisplatinGlutathione S-transferase Penzyme
DB00515CisplatinNAD(P)H dehydrogenase [quinone] 1enzyme
DB00515CisplatinGlutathione S-transferase Mu 1enzyme
DB00515CisplatinDNA-3-methyladenine glycosylasetarget
DB00515CisplatinSerum albumincarrier
DB00515CisplatinCopper transport protein ATOX1target
DB01206LomustineCytochrome P450 3A4enzyme
DB01206LomustineCytochrome P450 2D6enzyme
DB09035NivolumabProgrammed cell death protein 1target
DrugDrug NamePhaseStatusCount
DB00688Mycophenolate mofetil0Recruiting1
DB08870Brentuximab vedotin1Active Not Recruiting1
DB08870Brentuximab vedotin1Recruiting1
DB01590Everolimus1Active Not Recruiting1
DB09502Fludeoxyglucose F-181Recruiting1
DB09312Antilymphocyte immunoglobulin (horse)1 / 2Recruiting1
DB00098Antithymocyte immunoglobulin (rabbit)1 / 2Recruiting1
DB06769Bendamustine1 / 2Recruiting1
DB08870Brentuximab vedotin1 / 2Recruiting2
DB01008Busulfan1 / 2Recruiting1
DB00958Carboplatin1 / 2Recruiting1
DB00262Carmustine1 / 2Active Not Recruiting2
DB00493Cefotaxime1 / 2Active Not Recruiting2
DB00091Ciclosporin1 / 2Active Not Recruiting1
DB00631Clofarabine1 / 2Recruiting1
DB06189Clofarabine1 / 2Recruiting1
DB00531Cyclophosphamide1 / 2Active Not Recruiting2
DB00987Cytarabine1 / 2Active Not Recruiting2
DB00773Etoposide1 / 2Active Not Recruiting2
DB00773Etoposide1 / 2Recruiting1
DB01073Fludarabine1 / 2Active Not Recruiting2
DB00441Gemcitabine1 / 2Recruiting2
DB01181Ifosfamide1 / 2Recruiting1
DB06186Ipilimumab1 / 2Recruiting2
DB01042Melphalan1 / 2Active Not Recruiting2
DB12498Mogamulizumab1 / 2Recruiting1
DB14219Monomethyl fumarate1 / 2Recruiting1
DB00688Mycophenolate mofetil1 / 2Active Not Recruiting2
DB00688Mycophenolate mofetil1 / 2Recruiting1
DB09035Nivolumab1 / 2Recruiting3
DB09037Pembrolizumab1 / 2Recruiting1
DB00073Rituximab1 / 2Recruiting1
DB00864Tacrolimus1 / 2Active Not Recruiting1
DB00864Tacrolimus1 / 2Recruiting1
DB08870Brentuximab vedotin2Completed1
DB08870Brentuximab vedotin2Recruiting3
DB00493Cefotaxime2Active Not Recruiting1
DB00091Ciclosporin2Active Not Recruiting1
DB00531Cyclophosphamide2Active Not Recruiting1
DB01073Fludarabine2Active Not Recruiting1
DB00688Mycophenolate mofetil2Active Not Recruiting1
DB00091Ciclosporin3Active Not Recruiting1
DB01073Fludarabine3Active Not Recruiting1
DB00688Mycophenolate mofetil3Active Not Recruiting1
DB00688Mycophenolate mofetil3Completed1